Aripiprazole

Study	Exclusion reasons	Rmk	Reference
Sakai, 2017	inadequate or absent control group	EXCLUDED: Disproportionality Analysis of the Japanese Adverse Drug Event Report Database.	Sakai Drug Saf 2017; 40:1141-1146 10.1007/s40264-017-0560-z
Galbally, 2018	inadequate or absent control group	EXCLUDED: pregnancies included in the control group exposed to aripiprazole during pregnancy (they have ceassed during pregnancy but at an unknown time) => No adequate control group.	Galbally J Affect Disord 2018; 238:593-596
Ellfolk, 2019	not relevant exposure	EXCLUDED: Gestational diabetes not reported because not sure that exposure occurred before outcome.	Ellfolk Eur J Clin Pharmacol 2020; 76:107-115 10.1007/s00228-019-02769-z
Galbally, 2020	not relevant exposure	EXCLUDED: Gestational diabetes not reported because not sure that exposure occurred before outcome.	Galbally Aust N Z J Obstet Gynaecol 2020; 60:63-69 10.1111/ajo.12986
Frayne, 2018	same data already obtained by other studies	EXCLUDED: Answer of the author (Dr Frayne 21 Nov 2019) : 'Yes the 7 patients on Aripiprazole in the Frayne 2018 (n=7) publication will also be included in the Galbally 2018 (n=12).'	Frayne J Clin Psychopharmacol 2018; 38:563-569 10.1097/JCP.0000000000000964